Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
it would clear one compounding obstacle
This is educational content, not medical advice
Lillys first-mover advantage with tirzepatide in the dual-agonist space has so far put them ahead of these entrants
Intranasal delivery, though less studied with Dihexa, would theoretically provide direct CNS access with minimal systemic exposure, potentially requiring the least frequent administration to maintain effective brain tissue concentrations
US$ 27.96
US$ 28.32
US$ 28.34
US$ 28.47
US$ 24.24
US$ 22.43
US$ 22.75
